ArticleCancer medicine2026

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

Osamu Maeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.